Bio-Rad Laboratories Inc [BIO] stock is trading at $344.38, up 0.11%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The BIO shares have gain 4.83% over the last week, with a monthly amount glided 5.80%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Bio-Rad Laboratories Inc [NYSE: BIO] stock has seen the most recent analyst activity on October 01, 2024, when Citigroup upgraded its rating to a Buy and also boosted its price target to $400 from $350. Previously, Wells Fargo started tracking the stock with Equal Weight rating on August 28, 2024, and set its price target to $340. Citigroup downgraded its rating to a Neutral and decreased its price target to $365 on April 03, 2024. UBS initiated its recommendation with a Buy and recommended $395 as its price target on December 07, 2023. Wells Fargo started tracking with a Overweight rating for this stock on June 16, 2023, and assigned it a price target of $550. In a note dated December 07, 2022, RBC Capital Mkts initiated an Outperform rating and provided a target price of $565 on this stock.
Bio-Rad Laboratories Inc [BIO] stock has fluctuated between $262.12 and $387.99 over the past year. Currently, Wall Street analysts expect the stock to reach $400 within the next 12 months. Bio-Rad Laboratories Inc [NYSE: BIO] shares were valued at $344.38 at the most recent close of the market. An investor can expect a potential return of 16.15% based on the average BIO price forecast.
Analyzing the BIO fundamentals
Bio-Rad Laboratories Inc [NYSE:BIO] reported sales of 2.58B for the trailing twelve months, which represents a growth of 2.79%. Gross Profit Margin for this corporation currently stands at 0.54% with Operating Profit Margin at 0.12%, Pretax Profit Margin comes in at -0.39%, and Net Profit Margin reading is -0.3%. To continue investigating profitability, this company’s Return on Assets is posted at -0.07, Equity is -0.1 and Total Capital is 0.03. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.16.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 338.79 points at the first support level, and at 333.21 for the second support level. However, for the 1st resistance point, the stock is sitting at 348.54, and for the 2nd resistance point, it is at 352.70.
Ratios To Look Out For
For context, Bio-Rad Laboratories Inc’s Current Ratio is 6.14. Also, the Quick Ratio is 4.52, while the Cash Ratio stands at 0.83. Considering the valuation of this stock, the price to sales ratio is 3.73, the price to book ratio is 1.29.
Transactions by insiders
Recent insider trading involved Last Andrew J., Officer, that happened on Nov 06 ’24 when 3000.0 shares were purchased. Officer, Last Andrew J. completed a deal on Sep 12 ’24 to buy 1600.0 shares. Meanwhile, EVP, Chief Operating Officer Last Andrew J. sold 3000.0 shares on Sep 06 ’24.
